BioCentury
ARTICLE | Company News

Allogene gains Pfizer's off-the-shelf CAR T portfolio, announces $300M series A

April 6, 2018 8:51 PM UTC

Newly launched Allogene Therapeutics Inc. (South San Francisco, Calif.) will assume from Pfizer Inc. (NYSE:PFE) rights to off-the-shelf allogeneic CAR T products discovered by Cellectis S.A. (Euronext:ALCLS; NASDAQ:CLLS). Allogene also unveiled a $300 million series A round.

Under the deal, Allogene will gain exclusive rights to develop and commercialize 16 preclinical allogeneic CAR T products against specific targets. Pfizer gained rights to the preclinical assets under a 2014 deal with Cellectis, which remains eligible for milestone payments of up to $2.8 billion plus tiered royalties (see BioCentury, July 14, 2014)...